SCHEDULE: Iroquois Capital Discloses 9.99% Stake in Petros Pharma

Iroquois Capital Management and its principals, Richard Abbe and Kimberly Page, reported a 9.99% beneficial ownership stake in Petros Pharmaceuticals, Inc. as of December 21, 2025.

Summary

• Iroquois Capital Management, LLC, Richard Abbe, and Kimberly Page collectively reported beneficial ownership of 9.99% of Petros Pharmaceuticals, Inc.'s common stock.
• The ownership stake, as of December 21, 2025, includes 4,400,261 shares for Iroquois Capital and Kimberly Page, and 4,434,773 shares for Richard Abbe.
• This ownership is comprised of directly held common stock, warrants, and convertible preferred shares held by Iroquois Master Fund Ltd. and Iroquois Capital Investment Group LLC.
• The reported percentage gives effect to "Beneficial Ownership Blockers" (4.99% and 9.99%) which limit the exercise of warrants and conversion of preferred shares to prevent exceeding these thresholds.
• Due to these blockers, the reporting persons were unable to exercise all warrants or convert all preferred shares at the time of the event.
• The calculation of the 9.99% stake is based on 42,372,260 common shares outstanding as of November 12, 2025, plus 2,019,867 shares issuable upon exercise/conversion after applying the blockers.
• The securities were not acquired for the purpose of changing or influencing control of the issuer, except for activities solely related to a nomination under Rule 14a-11.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant institutional investor maintains a substantial stake, suggesting continued confidence, despite the limitations imposed by beneficial ownership blockers.

Positives

• A significant institutional investor, Iroquois Capital Management, maintains a substantial 9.99% beneficial ownership stake in Petros Pharmaceuticals, indicating continued investment interest.
• The filing clarifies the structure of Iroquois Capital's holdings, including common stock, warrants, and convertible preferred shares, demonstrating a diversified investment approach.

Negatives

• The presence of "Beneficial Ownership Blockers" (4.99% and 9.99%) limits the immediate ability of Iroquois Capital to fully exercise all warrants or convert all preferred shares, potentially restricting their flexibility or influence.

Risks

• The "Beneficial Ownership Blockers" on warrants and preferred shares mean that the reporting persons cannot fully realize their potential ownership if exercising/converting would exceed the 4.99% or 9.99% thresholds, which could impact their investment strategy or potential for increased influence.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance from the issuer regarding its future outlook.

Industry Context

StockSavvy.ai notes that a Schedule 13G filing indicates a passive investment by a significant shareholder, typically an institutional investor, holding more than 5% but less than 20% of a company's stock without the intent to control or influence management. For a pharmaceutical company like Petros, such a filing signals that a notable institutional player sees value in the company, potentially providing a degree of market validation, even if the investment is passive.

Comparison to Industry Standards

• StockSavvy.ai observes that a 9.99% beneficial ownership stake is a substantial position for an institutional investor in a small-cap pharmaceutical company.
• While specific comparable companies or projects are not detailed in this filing, such a stake by an investment firm like Iroquois Capital Management is generally viewed as a vote of confidence in the company's long-term prospects, aligning with typical institutional investment strategies in the biotech and pharma sectors where significant capital is often deployed in promising, albeit sometimes volatile, ventures.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Iroquois Capital Management may instill confidence among existing shareholders and potentially attract new investors, signaling institutional interest in Petros Pharmaceuticals.
• Company Management: Awareness of a large, passive institutional holder may influence management's strategic decisions, though the filing explicitly states no intent to control.

Key Dates

Recommendation

The filing indicates a stable, significant institutional ownership position, which is generally a neutral to slightly positive signal. However, it does not provide new fundamental information about Petros Pharmaceuticals' operations, financial performance, or strategic direction that would warrant a 'buy' or 'sell' recommendation. The 'Beneficial Ownership Blockers' also suggest a passive stance from the investor, limiting immediate upside from activist engagement. Therefore, a 'hold' recommendation is appropriate for investors awaiting further operational updates from the company.

Keywords

Petros Pharmaceuticals, Iroquois Capital Management, Richard Abbe, Kimberly Page, Schedule 13G, beneficial ownership, common stock, warrants, preferred shares, institutional investor, SEC filing, ownership blocker